Prof. Dr. med. Jörg Köhl

Transkript

1 Prof. Dr. med. Jörg Köhl Ausbildung Studium der Biologie: Universität Mainz Studium der Biologie: Universität Bochum Studium der Humanmedizin: Universität Mainz und Promotion (Dr. med.) Wissenschaftlicher Werdegang Assistent in der Weiterbildung, Institut für Medizinische Mikrobiologie, Medizinische Hochschule Hannover (MHH) Assistent in der Weiterbildung, Abteilung Pulmonologie, MHH Assistent in der Weiterbildung, Institut für Medizinische Mikrobiologie, MHH 1994 Facharzt für Medizinische Mikrobiologie und Infektionsepidemiologie 1995 Habilitation im Fach Medizinische Mikrobiologie; Ernennung zum Privatdozenten 1995 Oberarzt, Institut für Medizinische Mikrobiologie 1999 Ernennung zum apl. Professor Leitender Oberarzt; Institut für Medizinische Mikrobiologie, MHH Initiator und Sprecher des Transferbereichs 15: Die Bedeutung des Komplementspaltproduktes C3a als diagnostischer Frühmarker in der Sepsis Full Professor of Pediatrics (tenured), Division of Molecular Immunology, Cincinnati Children s Hospital Research Foundation, Cincinnati, USA Seit April-2008 Adjunct Professor of Pediatrics, Division of Molecular Immunology, Cincinnati Children s Hospital Research Foundation, Cincinnati, USA Seit April 2008 Direktor des Instituts für Systemische Entzündungsforschung, Medizinische Fakultät der Universität zu Lübeck und des Universitätsklinikums Schleswig- Holstein, Campus Lübeck. Drittmitteleinwerbung USA A. Thema: Molecular regulation of immune complex disease Förderung: National Institute of Health, R01, Principal Investigator (1 R01 AI A1) $ (Direct Costs) B. Thema: Molecular regulation of immune complex disease Förderung: National Institute of Health, R021, Principal Investigator (1 R21 AI ) $ (Direct Costs)

2 C. Thema: Complement in allergic asthma: The role of C3a and C5a Förderung: National Institute of Health, R01, Principal Investgator 1 R01 (AI A1) $ (Direct Costs) D. Thema: The C5a receptor as a drug target in kidney transplantation Förderung: Translational Research Initiative (TRI) of CCHMC, Principal Investigator $ 01/07/ /06/2007 E. Thema: Improving the preservation effect of organ transplantation solutions using the C5a receptor antagonist A8 Δ71-73 Förderung: Bridge the Gap Funding of CHMCC; Principal Investigator $ $ 01/07/ /06/2007 Deutschland A. Thema: Die pathophysiologische Rolle anaphylatoxischer Peptide., Prof. Dr. D. Bitter-Suermann ( ), Prof. Dr. Dr. W. Bautsch ( ) Förderung: DFG; Sonderforschungsbereich 244, Projekt B8 Zeitraum: x BAT IIa; 1 x BAT IIa/2, 1 x BAT Vc; DM Sachmittel BAT IIa, 1 BAT Vb DM Sachmittel; DM Investitionsmittel BAT IIa, 1 BAT Vb DM Sachmittel B. Thema: Generierung, Charakterisierung und Einsatz von C5a- und C5aR-Antagonisten zur Blockade inflammatorischer Prozesse von Entzündungszellen bei Rheumatischen Erkrankungen. Förderung: BMBF-Verbundprojekt; Teilprojekt B1 Zeitraum: BAT IIa/2; BAT Vc DM Sachmittel BAT IIa/2; BAT Vc DM Sachmittel C. Thema: Analyse humoraler und zellulärer Effektorsysteme bei der Xenotransplantation im diskordanten Kleintiermodell Meerschweinchen/Ratte. ; Dr. Andreas Meyer zu Vilsendorf Förderung: DFG; Sonderforschungsbereich 265; Projekt B16 Zeitraum:

3 BAT IIa/2; BAT Vc DM Sachmittel BAT IIa DM Sachmittel D. Thema: Die Bedeutung des Komplementspaltproduktes C3a als diagnostischer Frühmarker in der Sepsis. Sprecher: Förderung: DFG; Transferbereich 15 Beteiligte Institutionen: Medizinische Hochschule Hannover Unversitätsklinikum Magdeburg Universitätsklinikum Heidelberg Universitätsklinikum Mannheim Universitätsklinikum München-Grosshadern Beteiligtes Unternehmen: Biognosis GmbH; Jülich Zeitraum: März 1999 Februar x BAT IIa/2; 1 x BAT Vc, 1 student. Hilfskraft DM Sachmittel davon 1 x BAT IIa/2, 1 x BAT Vc, 1 student. Hilfskraft und DM Sachmittel im Institut für Med. Mikrobiologie (Gesamtfördersumme: DM) E. Thema: Die pathogenetische Rolle von C5a und Fc gamma- Rezeptoren in Typ III und Typ IV Überempfindlichkeitsreaktionen. Förderung: DFG-Normalverfahrten KO/1245 / 1-1 Zeitraum: Oktober 2000 September 2002 BAT IIa; BAT Vc; DM Sachmittel F. Thema: Die pathogenetische Rolle der Komplementspaltprodukte C3a und C5a bei der septischen Peritonitis Förderung: DFG-Normalverfahrten KO/1245 / 2-1 Zeitraum: März 2001 Februar 2003 BAT IIa; DM Sachmittel Thema: Die Rolle der Anaphylatoxine C3a und C5a in der Pthognese des experimentell-allergischen Asthmas. Förderung: DFG; Transregio 22, Teilprojekt A21 Zeitraum: Juli 2009 Juni 2013 E13; E13/2; Euro Sachmittel H. Thema: The impact of sleep on immunoregulatory functions of complement. Förderung: DFG; SFB 654, Teilprojekt C7 Zeitraum: Juli 2009 Juni 2013 Fördervolumen E13; Euro Sachmittel

4 Eingeladene Vorträge ( /2011) 1. A dual role for complement in experimental allergic asthma. Fraunhofer seminar: Models of asthma and COPD, January 21-22, Novel roles for complement in the regulation of adaptive immunity 9th EFIS-EJI Tatra Immunology Conference, Visegrad, Slovakia, September 4-8, Novel roles for complement in the regulation of adaptive immunity. 7 th International Conference on Innate Immunity, July 4-9, Rhodes, Greece. 4. The role of complement at the interface between innate and adaptive immunity. University of Greifswald, June 24, Novel roles for complement in the regulation of innate and adaptive immunity. Harvard Medical School, Department of Medicine, April The role of complement in immune complex diseases. XXXVII. Annual Meeting of the ADF (Arbeitsgemeinschaft Dermatologische Forschung), Lübeck, The complex role of C5a in experimental goodpasture nephritis. 4 th International Workshop on Thrombotic Microangiopathies, Weimar, Germany, October 1-3, The role of complement at the interface between innate and adaptive immunity. Hycult Biotechnology, The Netherlands, November 12, Cross-talk beeetween IgG Fc and C5a receptors regulates neutrophilic inflammation in immune complexe diseases. Neutrophil granulocytes revisited: International symposium on novel functions of neutrophils granulocytes, Lübeck, Germany, September 10-12, The complement system. 12 th European Meeting on complement in human disseaes. Visegrad, Hungary, September 5-8, A novel role for C5L2 in the pathogenesis of anti-gbm nephritis. Session IV: Complement ; 6 th International Conference on Innate Immunity, Crete, Greece, June 21-26, Complement: Sensor and effector system of innate and adaptive immune responses. 9 th Beaune Seminar in Transplant Research: Transplantation tolerance induction at the cross-roads between innate and adaptive immunity, Burgundy, May Danger sensing by complement: the curious case of an anaphylatoxin receptor, Department of Clinical Immunology, Uppsala University, March 19, Danger sensing by complement: the curious case of an anaphylatoxin receptor, MRC Centre for Transplantation at King s College London, March 6, The role of complement as a danger sensing system regulating adaptive immune responses, 5 th Spring School of Immunology, Kloster Ettal, March 2-6, The role of complement as a danger sensing system regulating adaptive immune responses, Institute of Medical Microbiology and Immunology, Aarhus, February 19, The role of complement in danger sensing and transmission. University Ulm, Department of Surgery III, February 17, Introduction to Complement and it's position in the immune system, XXII st International Complement Workshop, Keynote speaker, Teaching day: September 28 October 2,

5 Basel, Switzerland, C5a receptor is part of a novel pathogen recognition system, Session IV: Complement ; 4 th International Conference on Innate Immunity, June 4-9, Crete, Greece C5a receptor is part of a novel pathogen recognition system. 4 th International Conference on Innate Immunity, June 21-26, Crete, Greece. Cross-talk of innate immune receptors. 13 th International Congress of Immunology, Rio de Janeiro, Brazil, August 21-25, The role of complement in danger sensing and transmission. 4th International Workshop on Complement Associated Diseases, Animal Models, and Therapeutics, Porto Heli, Greece, June 10-15, Cross-talk of innate immune receptors. Washington University, St. Louis; Division of Rheumatology, April 12-13, Cross-talk between pattern recognition receptors systems. Cleveland Clinic, Department of Pathobiology, February 26-27, Immunoregulation at mucosal surfaces: cross-talk between complement and toll-like receptors. University of Lübeck, February, 22-23, Immunoregulation at mucosal surfaces: cross-talk between complement and toll-like receptors. University of Münster, February, 20-21, Cross-talk between complement and TLRs. 35 th Autumn Immunology Conference. Symposium: Complement in Health and Disease., Chicago, November 18-20, Self, Non-Self and Danger: a complementary view. 4 th International Conference on Innate Immunity, Corfu Greece, June 4-9, Allergy, infection and the adaptive immune response: a complementary view. University of Irvine, CA, UCI Immunology Seminar Series, March 02, Crossroads between Innate and Adaptive Immunity: The role of Complement. Archemix Corporation, Cambridge, MA, USA, November 6, C5a negatively regulates toll-like receptor 4-induced immune responses, University of Jena, Germany, October 14, A critical role for complement in the sensitization and the effector phase of experimental allergic asthma. Swiss Institute for Allergy and Asthma Research, Davos, Switzerland, October 10, Complement in Inflammatory Disorders, 10 th European Meeting on Complement in Human Disease, Heidelberg, Germany, September 9-13, Crossroads between Innate and Adaptive Immunity: The role of Complement, University of Ulm, Germany, June 24, The role of complement in the regulation of adaptive immune responses. Jerini AG, Berlin, Germany, May 5, C5a regulates type 2 adaptive immunity in allergic asthma. 3rd Workshop on Complement Associated Diseases, Animal Models, and Therapeutics, Rhodes, Greece, June 5-10, Cross-talk between complement and Toll-like receptors: complement 5a plays a crucial gatekeeper role in TLR-4 mediated regulation of adaptive immunity. 3 rd International Conference on Innate Immunity, Crete, Greece, October 10-15, A critical role of C5a in the sensitization and the effector phase of experimental allergic

6 asthma. XX th International Complement Workshop, Hawaii, USA, June Complement 5a mutants as complement 5a receptor antagonists: from phage display to animal models. University of Maastricht, Department of General Surgery; The Netherlands, March Assessing the progression of the inflammatory response in SIRS and sepsis: The value of measuring C3a, IL-6, and PCT. 6th World Congress on Trauma, Shock, Inflammation and Sepsis Pathophysiology, Immune Consequences and Therapy, Symposium XXIV, Munich, Germany, March Complement 5a mutants as complement 5a receptor antagonists: from phage display to animal models. University of Frankfurt/Main, Department of Biochemistry, Germany, March Complement in allergic asthma: friend and foe. Immunological Colloquium Series, Medical School Hannover, Germany, March Reviewer für folgende Institutionen der Forschungsförderung ( ) Technology Foundation STW (Niederlande) The Wellcome Trust (United Kingdom;) The Eli and Edythe L. Broad Foundation (USA) BioProfil Nutrigenomik (BMBF) Deutsche Forschungsgemeinschaft (DFG) Landesstiftung Baden-Württemberg National Institute of Health (NIAID HAI Study Section; Februar 2005) National Institute of Health (NIAID Special Emphasis Panel [ZRG1 IMM B ] November 2005 National Institute of Health (NIAID HAI Study Section; Februar 2006) National Institute of Health (NIAID Special Emphasis Panel [ZRG1 IMM B 02] Juli 2006